CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-29 | Patel Snehal CEO and CFO | Purchase | +4,000 | $15.19 | $61K | 2,729,886 |
| 2022-12-16 | Patel Snehal CEO and CFO | Purchase | +1,000 | $13.01 | $13K | 2,725,886 |
| 2022-12-16 | Thompson Jaye VP Clinical Reg Affairs | Purchase | +250 | $12.94 | $3K | 256,495 |
| 2022-12-09 | Patel Snehal CEO and CFO | Purchase | +2,000 | $13.11 | $26K | 2,724,886 |
| 2022-12-02 | Patel Snehal CEO and CFO | Purchase | +1,000 | $13.84 | $14K | 2,722,886 |
| 2022-12-02 | Thompson Jaye VP Clinical Reg Affairs | Purchase | +250 | $13.98 | $3K | 256,245 |
| 2022-11-02 | Patel Snehal CEO and CFO | Purchase | +2,000 | $8.79 | $18K | 2,721,886 |
| 2022-10-14 | Patel Snehal CEO and CFO | Purchase | +3,000 | $9.75 | $29K | 2,719,886 |
| 2022-10-07 | Patel Snehal CEO and CFO | Purchase | +2,000 | $9.72 | $19K | 2,716,886 |
| 2022-09-30 | Patel Snehal CEO and CFO | Purchase | +1,000 | $9.46 | $9K | 2,714,886 |
| 2022-09-29 | Patel Snehal CEO and CFO | Purchase | +1,000 | $9.23 | $9K | 2,713,886 |
| 2022-06-24 | Patel Snehal CEO and CFO | Purchase | +22,535 | $9.13 | $206K | 2,706,421 |
| 2022-06-24 | Patel Snehal CEO and CFO | Purchase | +6,465 | $9.13 | $59K | 2,712,886 |
| 2022-06-22 | Daugherty Frank Joseph Chief Medical Officer | Grant or award · Stock Options | +104,890 | 104,890 | ||
| 2022-06-22 | Patel Snehal CEO and CFO | Grant or award · Stock Options | +1,048,723 | 1,048,723 | ||
| 2022-06-22 | Patel Snehal CEO and CFO | Grant or award · Stock Options | +25,008 | 1,073,731 | ||
| 2022-06-22 | Thompson Jaye VP Clinical Reg Affairs | Grant or award · Stock Options | +149,818 | 149,818 | ||
| 2022-06-22 | Hallock Kenneth Director | Grant or award · Stock Options | +41,349 | 41,349 | ||
| 2022-06-22 | Rothe Eric Director | Grant or award · Stock Options | +41,349 | 41,349 | ||
| 2022-06-22 | McWilliams David Director | Grant or award · Stock Options | +61,984 | 61,984 |
Page 5 of 10 · 190 trades